- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01164969
Mixed Strain H. Pylori Infection in Patients Who Have Problems With Eradication of H. Pylori
16. juli 2010 opdateret af: University Medical Centre Ljubljana
Multi Locus Sequence Typing (MLST) Used as Tool to Confirm Ability of Susceptible Helicobacter Pylori Strains to Gain Resistance to Clarithromycin During Eradication Therapy Independently of Mixed Strain Helicobacter Pylori Infection
The purpose of this study is to determine whether mixed H. pylori strain infection is the reason for eradication failure during treatment of H. pylori infection.
The investigators present the results got from extensive sampling of biopsy samples taken from individuals diagnosed with H. pylori connected disease.
The investigators were looking for individuals that were not able to eradicate H. pylori although they had susceptibility testing tailored antibiotic therapy.
On their control visit after 2 months they presented again with H. pylori although at their first visit they had H. pylori isolated from biopsy sample sensitive to all antibiotics prescribed.
Multi Locus Sequence Typing (MLST) was used to prove the sequence type of H. pylori and E test was used to determine susceptibility of H. pylori to antibiotics.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
10
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Ljubljana, Slovenien, 1000
- Institute of microbiology and immunology
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
The investigators invited people who were not able to eradicate H. pylori although at their first visit they had H. pylori sensitive to all antibiotics tested.
At first visit all patients had stomach biopsy sample taken and H. pylori isolated and therapy prescribed.
If they did not eradicate bacteria after 2 months they were again invited to control visit to define the problem and appropriate therapy prescribed.
They were again invitation to control visit at the end of June 2010 to see the outcome of therapy.
Beskrivelse
Inclusion Criteria:
- People who have H. pylori sensitive to all antibiotics before therapy and and do not eradicate H. pylori after appropriate antibiotic therapy.
Exclusion Criteria:
- People who did not eradicate H. pylori because of primary resistance to antibiotics.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
H. pylori eradication failure
People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
|
Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sequence type of H.pylori determined with MLST as a good evidence that people are infected with only one strain of H. pylori
Tidsramme: Six months after first visit the strains from before/after therapy will be inspected with MLST to see if people have mixed strain infection.
|
The investigators assume that people that are not able to eradicate infection with H. pylori although they have never been treated for such infection and they have taken appropriate therapy, have such problems because H. pylori is capable to escape from immune response.
The investigators will define if patients have the same H. pylori sequence type through longer period and that such H. pylori is capable to develope resistance to clarithromycin very quickly.Such patients can eliminate H. pylori if we check the infection status more often and give them more suitable antibiotic therapy.
|
Six months after first visit the strains from before/after therapy will be inspected with MLST to see if people have mixed strain infection.
|
|
Sequence type of H.pylori determined with MLST as a good evidence that people are infected with only one strain of H. pylori
Tidsramme: 9 months after first visit to see if people still have H. pylori due to insufficient immune response.
|
The investigators assume that people that are not able to eradicate infection with H. pylori although they have never been treated for such infection and they have taken appropriate therapy, have such problems because H. pylori is capable to escape from immune response.
The investigators will define if patients have the same H. pylori sequence type through longer period and that such H. pylori is capable to develope resistance to clarithromycin very quickly.Such patients can eliminate H. pylori if we check the infection status more often and give them more suitable antibiotic therapy.
|
9 months after first visit to see if people still have H. pylori due to insufficient immune response.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Studieleder: Alojz Ihan, MD. PhD, Institute of mircobiology and immunology, Slovenia
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2008
Primær færdiggørelse (Faktiske)
1. december 2009
Studieafslutning (Faktiske)
1. juli 2010
Datoer for studieregistrering
Først indsendt
13. juli 2010
Først indsendt, der opfyldte QC-kriterier
16. juli 2010
Først opslået (Skøn)
19. juli 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
19. juli 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
16. juli 2010
Sidst verificeret
1. juli 2010
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IMI2010-2
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med H. Pylori Eradication Failure
-
Catalysis SLRekrutteringH Pylori Infektion | H Pylori Gastritis | Gastritis forbundet med Helicobacter pylori | H Pylori udryddelse | MaveslimhindelæsionSerbien
-
Asian Institute of Gastroenterology, IndiaIkke rekrutterer endnu
-
Beni-Suef UniversityAfsluttet
-
Benha UniversityAfsluttet
-
Ramathibodi HospitalAfsluttetH Pylori udryddelseThailand
-
Tanta UniversityAfsluttet
-
Christopher C. Thompson, MD, MScErbe Elektromedizin GmbHRekrutteringHelicobacter pylori infektion | H. Pylori-infektion | Helicobacter pylori | Helicobacter Pylori mave-tarmkanalens infektion | H. Pylori Gastrointestinal sygdomForenede Stater
-
University of LatviaNational Institute of Public Health, Slovenia; Iuliu Hatieganu University... og andre samarbejdspartnereRekrutteringMavekræft | H Pylori Infektion | H Pylori udryddelse | H-pyloriPolen, Kroatien, Irland, Letland, Rumænien, Slovenien
-
Assistance Publique - Hôpitaux de ParisUkendtH Pylori udryddelse | H Pylori Infektion Udryddelse | Antibiotika Terapeutiske StrategierFrankrig
-
University of MiamiNRG Oncology; Phathom PharmaceuticalsAktiv, ikke rekrutterendeMavekræft | H. Pylori-infektion | Gastritis H pyloriForenede Stater